A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.
The European League Against Rheumatism (EULAR) updates its recommendations for diagnosing gout, putting emphasis on three diagnostic approaches: establishing monosodium urate crystal deposition via synovial fluid analysis, identifying suggestive and associated clinical features of gout and hyperuricaemia, or performing imaging studies for evidence of MSU crystals.
The selective Janus kinase 1 inhibitor upadacitinib demonstrated sustained efficacy and safety beyond 12 weeks in patients with moderate-to-severe rheumatoid arthritis (RA) who had inadequate response or were refractory to disease-modifying antirheumatic drugs (DMARDs), according to the interim results of the ongoing extension phases of SELECT-NEXT* and SELECT-BEYOND** presented at EULAR 2019.
Both inflammatory bowel disease (IBD) and type 1 diabetes (T1D) are highly prevalent among patients who eventually develop rheumatoid arthritis (RA), indicating that these two conditions are potential risk factors for RA, according to a study presented at EULAR 2019.
Early use of the oral Janus kinase 1/2 inhibitor baricitinib led to enhanced clinical, functional, and radiographic efficacy compared with methotrexate monotherapy in patients with rheumatoid arthritis (RA), according to data presented at EULAR 2019.
The risk of serious infection* among patients receiving systemic therapy for psoriasis differs by treatment, with apremilast, etanercept, and ustekinumab associated with a reduced risk of serious infection than methotrexate, according to an observational study.
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.
Monotherapy with tocilizumab (TCZ) shows good tolerability profile and results in remission in most patients with polymyalgia rheumatica (PMR) despite the absence of glucocorticoids, according to the 2-year results of a single-centre, open‐label pilot study.